» Articles » PMID: 12658112

Effects of Acamprosate on Excitatory Amino Acids During Multiple Ethanol Withdrawal Periods

Overview
Specialty Psychiatry
Date 2003 Mar 27
PMID 12658112
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Our previous studies on the effects of acamprosate on enhanced locomotion during repeated withdrawals are now extended to the effects of acamprosate on excitatory amino acids in the hippocampus during repeated ethanol withdrawals.

Methods: In this study, Wistar rats were made ethanol dependent by 4 weeks of vapor inhalation. After this first cycle of chronic ethanol treatment, rats underwent repeated and alternate cycles of 24 hr withdrawals and 1 week of chronic ethanol treatment. The microdialysis technique was used together with high-performance liquid chromatography and electrochemical detection to quantify different amino acids such as aspartate and glutamate.

Results: An intraperitoneal administration of acamprosate (400 mg/kg) to naïve rats did not alter aspartate or glutamate levels compared with the saline groups. During the first cycle of ethanol withdrawal, the administration of acamprosate (400 mg/kg, intraperitoneally) 2 hr after the commencement of ethanol withdrawal decreased both aspartate and glutamate microdialysate levels when compared with their respective saline group. Acamprosate administration also significantly decreased glutamate levels during the third withdrawal compared with the saline group, whereas no changes were seen in aspartate levels.

Conclusion: The results of this work demonstrate that acamprosate reduced the excitatory amino acid glutamate increase observed during repeated ethanol withdrawal. These effects of acamprosate may provide a protective mechanism against neurotoxicity by reducing excitatory amino acids, particularly glutamate.

Citing Articles

Calcium chloride mimics the effects of acamprosate on cognitive deficits in chronic alcohol-exposed mice.

Pradhan G, Melugin P, Wu F, Fang H, Weber R, Kroener S Psychopharmacology (Berl). 2018; 235(7):2027-2040.

PMID: 29679288 PMC: 10766324. DOI: 10.1007/s00213-018-4900-1.


Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety.

Schaefer T, Davenport M, Grainger L, Robinson C, Earnheart A, Stegman M J Neurodev Disord. 2017; 9:6.

PMID: 28616095 PMC: 5467053. DOI: 10.1186/s11689-017-9184-y.


Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects.

Hinton D, Vazquez M, Geske J, Hitschfeld M, Ho A, Karpyak V Sci Rep. 2017; 7(1):2496.

PMID: 28566752 PMC: 5451388. DOI: 10.1038/s41598-017-02442-4.


Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol Dependence.

Frye M, Hinton D, Karpyak V, Biernacka J, Gunderson L, Feeder S J Clin Psychopharmacol. 2016; 36(6):669-674.

PMID: 27755217 PMC: 6352725. DOI: 10.1097/JCP.0000000000000590.


A sex difference in oxidative stress and behavioral suppression induced by ethanol withdrawal in rats.

Jung M, Metzger D Behav Brain Res. 2016; 314:199-214.

PMID: 27503149 PMC: 5002225. DOI: 10.1016/j.bbr.2016.07.054.